Global Enzyme Inhibitors Market Report 2017: 2015-2016 Data, Estimates for 2017 & CAGR Projections to 2022 – Research and Markets

December 19, 2017

DUBLIN–(BUSINESS WIRE)–The "Global
Markets for Enzyme Inhibitors" report has been added to Research
and Markets' offering.

The Global Market for Enzyme Inhibitors Should Reach $179.9
Billion by 2022 from $168 Billion in 2017 at a CAGR of 1.4%

Report Includes

  • An overview of the global markets for enzyme inhibitors.
  • Analyses of global market trends, with data from 2015 and 2016,
    estimates for 2017, and projections of compound annual growth rates
    (CAGRs) through 2022.
  • Detailed analysis of the enzyme inhibitors industry structure.
  • A look at applications for enzyme inhibitors, with emphasis on the
    usage of the inhibitors in therapeutic categories and various disease
    sectors.
  • Coverage of significant patents and their allotments in each category.
  • Profiles of major players in the industry.

Enzyme inhibitors drugs are drugs that help to treat chronic diseases
such as cardiovascular disease, gastrointestinal disease, acquired
immunodeficiency syndrome, cancer, hepatitis, men's-health-related
conditions (erectile dysfunction, benign prostatic hyperplasia,
alopecia), diabetes and various others (rheumatoid arthritis, psoriasis,
Parkinson's disease, influenza, etc.). This report focuses on the global
market of enzyme inhibitor drug products and provides an updated review
including its applications in various arenas of disease sectors.

The period of the current report saw an enormous number of new approvals
and new indication approvals. New enzyme inhibitor categories gained
entries in the market. In comparison with the last report, therefore, a
number of new enzyme inhibitor types have been included in this report.

They are integrase inhibitors, PCSK9 inhibitors, PARP inhibitors, PDE4
inhibitors, DPP-4 inhibitors and SGLT-2 inhibitors. Certain other
categories that had mentionable markets were also included such as
AChEIs, 5-ARI inhibitors, XOIs and MAOIs. The market had started to
decline due to patent expiries since 2010-2011, and the trend was seen
to accelerate during the period of the current report.

Key Topics Covered:

1: Introduction

2: Summary And Highlights

3: Market And Technology Background

4: Market Breakdown By Technology Type And Region

5: Market Breakdown By Application

6: Industry Structure

7: Patent Review/ New Developments

8: Analysis Of Market Opportunities

9: Company Profiles

  • Abbott Laboratories
  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb
  • Cipla Usa Inc.
  • Clovis Oncology
  • Daiichi-Sankyo Co. Ltd
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly And Co.
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences Inc.
  • Glaxosmithkline Plc
  • Glenmark Pharmaceuticals Limited
  • Incyte Corp.
  • Janssen Global Services Llc
  • Kowa Pharmaceuticals America Inc.
  • Lupin Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Novartis Holding Ag
  • Pfizer Inc.
  • Sanofi Genzyme Corp.
  • Servier
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceuticals Co.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International Inc.
  • VIIV Healthcare
  • Vivus Inc.
  • Zydus Cadila

For more information about this report visit https://www.researchandmarkets.com/research/lczcmz/global_enzyme?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Enzymes